



The Society for Medicines Research

Reducing Attrition through Early Assessment of Drug Safety

Follow us on:



Follow us on:



13th March 2014
NHLI, Kensington, London

Sponsored By



Reducing Attrition through Early Assessment of Drug Safety

Programme:

Drug toxicity remains one of the main causes of compound attrition in the drug development process. Compounds displaying organ, mechanism-based or off-target toxicity are just some of the safety issues that have contributed to drug development failures, and the need for robust early drug safety screening in an integrative manner is clear.

In the last decade, an increased understanding of the molecular basis for some of these toxicities and the advancement of technologies designed to screen for them has improved options for screening out potential compound liabilities earlier in the research phase. Advances include the use of human induced pluripotent stem cells and miniaturised mimics of human organs. New markers of toxicity are being investigated at the RNA level, using metabolomics and through application of bioinformatic approaches. In addition, technologies have been developed to gather data on broad compound promiscuity at the protein level using panels of off-target activity as markers of general promiscuity.

This meeting will bring together a range of international experts from both industry and academia to present the new technologies and their applications in early drug safety assessment. The meeting will be of great interest to anyone involved in drug discovery and development, or has an interest in the science behind drug safety screening

09.00 Arrival, Registration and Coffee

10.00 **Welcome and Announcements**

Session 1 Chair: Dr David Pryde

10.05 Risk management of medicines: the need for early planning

Professor Frank W Bonner, Chief Executive, Stem Cells for Safer Medicines, London, UK

10.50 Early use of pharmacological promiscuity indices to select the best compounds

Gareth Waldron, Pfizer, UK.

11.35 Reducing attrition via bioinformatics approaches in safety and toxicology

Samiul Hasan, GlaxoSmithKline, UK

12.20 Lunch

Reducing Attrition through Early Assessment of Drug Safety

Programme:

13.30 **Session 2 Chair Dr Julie Holder**

Organs-on-chips

Dr Anthony Bahinski, *Advanced Technology Team, Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, US*

14.15 Circulating miRNAs as markers of toxicology

Chris Goldring, *Institute of Translational Medicine, Liverpool University, UK.*

15.00 Tea

Session 3 Chair Dr Wendy Alderton

15.30 Use of metabolomics to assess drug toxicity during pre-clinical research

Dr. Gina Montoya, *BASF, Germany.*

16.15 Use of human iPS cells early in drug discovery to inform on toxicological hazard

Marc Peschanski, *I-STEM, INSERM, Paris*

17.00 **Concluding remarks and close of meeting**

MEMBERSHIP

The SMR is a multi-disciplinary society for all those engaged in drug research and development and this broad remit is reflected in the composition of the committee and the range of topics covered by our high-quality one-day meetings.

In line with the SMR's educational charter, the membership subscription of the SMR is deliberately low at £25* (Sterling) per annum (UK tax payers can claim relief on the payment). Members can attend the one-day meetings at substantially reduced rate and receive the SMR Newsletter which is published twice yearly.

Follow us on: **JOIN US ONLINE AT WWW.SMR.ORG.UK**

Follow us on:



Reducing Attrition through Early Assessment of Drug Safety

Name: (Incl. Title)

Address: (Incl. Company Name)

Tel: Fax:

Email:

Dietary Requirements: ☐ Vegetarian: Other:
☐ Please tick if you need a car parking space

Registration Fees: Non-Members: £125 ☐ Honorary Life Member
Retired members: £35 ☐ (FREE) ☐

SMR members: £85 ☐

Students: £35 ☐

Note: Unemployed rates and student bursaries are available but places are limited - please contact the Secretariat for more details.

Could you please indicate to us how you heard about this conference:

(e.g. Colleague/supervisor/SMR web site/other website/media/other society or group)

Cheque:

If you wish to pay by cheque, then please send your cheque made payable to **Society for Medicines Research**, together with this form to the address given below.

Credit/Debit Card:

To pay by Visa/Eurocard/MasterCard/Switch/Delta/ConnectCard or American Express simply enter your card details below.

Card Nr: Expiry Date:

Cardholders address if different from above:

Please note that deductions will be shown on your statement with the reference

'association enterprises Ltd'

Names and addresses of delegates will be included in a list given to all attendees. If you do **NOT** want your name to appear please tick this box. ☐

Fees once paid are not refundable unless a cancellation is received at least 5 working days prior to the event. Delegate substitutes are permitted at any time. Join on-line at www.smr.org.uk or through our secretariat at the address given below.

DATA PROTECTION ACT: By completing and returning this form you agree to allow the Society for Medicines Research to hold and process data about your registration on computer and to pass this information on to 3rd parties as may be required in order to provide the services being offered. The Society for Medicines Research does not rent or sell this data to other companies or organisations.

Society for Medicines Research

**Q House, Troon Way Business Centre, Humberstone Lane,
Thurmaston, Leicester, LE4 9HA
Tel: 0116 2747356 Fax: 0116 2747365**

Follow us on:



**Register on-line at:
www.smr.org.uk**

